There is big money to be made from psychedelic stocks and the companies planning to treat depression will be the winners.
ATLANTA, Feb. 11, 2021 (GLOBE NEWSWIRE) — OTC Stock Review: Unless you have been hiding under a rock for the last year, you probably know psychedelic stocks have been among the biggest movers on Wall Street. New leaders may emerge, but the reason for this increased interest in psychedelics is improved mental health. We have said it before, and we will say it again, the real money in psychedelics will be made from FDA approved drugs for the treatment of depression and mental health. Depression is a common mental disorder affecting more than 264 million people worldwide. Finding a treatment for those 264 million people suffering from depression are what it’s all about.
No one deserves to live in a state of depression. Mental health experts find a strong link between loneliness and depression and drug overdoses. According to national drug abuse data, drug overdoses have increased 42% since Covid-19 reared its ugly head. As a result, mental health disorders are on the rise in every country and could cost the global economy up to $16 trillion annually by 2030. The numbers are staggering, but outweighed by the loss of human lives. Mental health is something every one of us should be talking about. Psychedelic-assisted psychotherapy could provide needed options for debilitating mental-health disorders including PTSD, major depressive disorder, alcohol-use disorder, anorexia nervosa and more that kill thousands every year in the United States, and cost billions worldwide in lost productivity.